

RUNAWAY

AFFORDABLE PRICES FOR REAL CURES




Americans Support Taking Action on Runaway Rx Prices

Americans are growing impatient with high cost drugs, as revealed in a new Kaiser Family Foundation [poll](#).



- ✓ **7 in 10 Americans think drug prices are unreasonable.**
- ✓ **86 percent favor greater price transparency.***

 Democrats	 Republicans	Independents
90%	82%	84%

- ✓ **3 out of 4 say Americans pay higher prices for the same drugs than people in Canada, Mexico and Western Europe.**

"In April, the nonpartisan Kaiser Family Foundation was surprised by a poll showing more Republicans view drug prices as the No. 1 health care priority than repealing Obamacare. So the foundation looked further, asking Americans what steps they would back to reduce drug costs."

– [Politico](#)

* [AB 463 \(Chiu\)](#), a two-year bill, is California's policy solution to drug price transparency. The bill was supported by a diverse group of nearly 50 stakeholders who are often on opposite sides, including health plans and consumer groups, business and labor.

AB 463



will Open Up the Black Box

AB 463 requires drug manufacturers to report select cost information for drugs priced above \$10,000, including:

- ✓ Research & development costs paid in development of qualifying drug
- ✓ Marketing & advertising costs
- ✓ Costs covered by government sources in development of drug, including subsidies & grants
- ✓ Costs for materials & manufacturing
- ✓ History of the Average Wholesale Price & Wholesale Acquisition Cost for the drug
- ✓ Total profit attributable to the drug

CAHP's RunawayRx campaign highlights the trend of rising prescription drug prices to provide Californians with a full picture of the state of health care costs and to encourage a path toward more sustainable and affordable pricing.